The US Food and Drug Administration (FDA) has approved fitusiran (Qfitlia, Sanofi) for bleeding prophylaxis in patients aged 12 years or older with hemophilia A and B with or without factor VIII ...

Opens in a new tab or window The FDA approved fitusiran (Qfitlia) as prophylaxis to prevent or reduce bleeding episodes in adults and children ages 12 years and up with hemophilia A or B ...

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on the safety and efficacy of fitusiran (Qfitlia; Sanofi). Fitusiran (Qfitlia ...

M.D., Sanofi’s hemophilia program leader, said in an interview with Fierce Pharma. “We’re obviously excited about fitusiran because it’s the first therapy in the United States that can be ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

Qfitlia Becomes the Sixth Alnylam-Discovered RNAi Therapeutic Approved by U.S. FDA and First and Only to Treat Hemophilia A or ... approval of Qfitlia™ (fitusiran), the sixth Alnylam-discovered ...

Qfitlia is indicated in the U.S. for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B ...

The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...